VJHemOnc is committed to improving our service to you

ISAL 2017 | Exploring combinatorial approaches in acute myeloid leukemia (AML) treatment

VJHemOnc is committed to improving our service to you

Francesco Lo-Coco

Francesco Lo-Coco, MD, from the University Tor Vergata, Rome, Italy, discusses the potential of combinatorial treatment approaches for acute myeloid leukemia (AML) at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany. Arsenic trioxide (ATO), which is used to treat acute promyelocytic leukemia (APL, APML), is not effective on its own in acute myeloid leukemia (AML). Prof. Lo-Coco suggests that new combinatorial approaches should be explored in other subsets of leukemia, using ATO together with new or conventional agents. He highlights the importance of collaboration in both pre-clinical and clinical studies, and points out that combinatorial approaches represent a good opportunity, as several combinations have not yet been explored.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter